Martin Worley Group Buys Shares of 10,168 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Martin Worley Group bought a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,168 shares of the specialty pharmaceutical company’s stock, valued at approximately $86,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Intech Investment Management LLC acquired a new position in KalVista Pharmaceuticals during the third quarter valued at approximately $126,000. Citigroup Inc. increased its stake in shares of KalVista Pharmaceuticals by 6.8% in the 3rd quarter. Citigroup Inc. now owns 305,504 shares of the specialty pharmaceutical company’s stock valued at $3,538,000 after purchasing an additional 19,440 shares during the last quarter. FMR LLC raised its holdings in shares of KalVista Pharmaceuticals by 22.9% during the 3rd quarter. FMR LLC now owns 66,423 shares of the specialty pharmaceutical company’s stock worth $769,000 after buying an additional 12,397 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of KalVista Pharmaceuticals by 1,335.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 43,296 shares of the specialty pharmaceutical company’s stock worth $501,000 after buying an additional 40,280 shares during the last quarter. Finally, PDT Partners LLC acquired a new stake in KalVista Pharmaceuticals in the third quarter valued at about $260,000.

Analyst Upgrades and Downgrades

KALV has been the subject of several research analyst reports. Bank of America began coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Jones Trading restated a “buy” rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $24.83.

KalVista Pharmaceuticals Stock Down 0.5 %

Shares of KalVista Pharmaceuticals stock opened at $11.09 on Thursday. The stock has a market cap of $551.35 million, a price-to-earnings ratio of -3.05 and a beta of 0.39. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The company’s fifty day moving average is $10.73 and its 200 day moving average is $10.26.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, major shareholder Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were bought at an average cost of $9.22 per share, with a total value of $134,261.64. Following the purchase, the insider now owns 5,012,796 shares in the company, valued at $46,217,979.12. This trade represents a 0.29 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 6,669 shares of KalVista Pharmaceuticals stock in a transaction on Friday, March 7th. The stock was sold at an average price of $11.97, for a total transaction of $79,827.93. Following the transaction, the chief executive officer now directly owns 287,811 shares of the company’s stock, valued at $3,445,097.67. This represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have purchased 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. Corporate insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).